

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH2/21 - Blood Group Serology

Deadline: 04.06.2021

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set 1 and 2

(700) AB0 blood group

E1 and S1 (6) APR	>>>	3	Blood group: A	2,1 %
(14) Bio-Rad	>>>	44	Blood group: A	31 %
(40) Ortho Clinical Diagnostics	>>>	2	Blood group: A	1,4 %
(52) Dynex	>>>	1	Blood group: A	0,71 %
(64) Exbio Olomouc	>>>	10	Blood group: A	7,1 %
(80) DiaMed	>>>	15	Blood group: A	11 %
(159) Grifols	>>>	28	Blood group: A	20 %
(172) Immucor	>>>	1	Blood group: 0	0,71 %
	>>>	16	Blood group: A	11 %
(173) Sanguin	>>>	8	Blood group: A	5,7 %
(174) IVT Imuno	>>>	7	Blood group: A	5,0 %
(203) ANTITOXIN	>>>	1	Blood group: A	0,71 %
(999) another manufacturer	>>>	4	Blood group: A	2,9 %
Total per sample: n = 140		Success: 99 %		
E2 and S2 (6) APR	>>>	3	Blood group: B	2,1 %
(14) Bio-Rad	>>>	44	Blood group: B	31 %
(40) Ortho Clinical Diagnostics	>>>	2	Blood group: B	1,4 %
(52) Dynex	>>>	1	Blood group: B	0,71 %
(64) Exbio Olomouc	>>>	10	Blood group: B	7,1 %
(80) DiaMed	>>>	15	Blood group: B	11 %
(159) Grifols	>>>	28	Blood group: B	20 %
(172) Immucor	>>>	17	Blood group: B	12 %
(173) Sanguin	>>>	8	Blood group: B	5,7 %
(174) IVT Imuno	>>>	7	Blood group: B	5,0 %
(203) ANTITOXIN	>>>	1	Blood group: B	0,71 %
(999) another manufacturer	>>>	4	Blood group: B	2,9 %
Total per sample: n = 140		Success: 100 %		
Total success: 99 %				

(703) A subgroup

E1 and S1 (0) not specified	>>>	44	A subgroup A1	100 %
Total per sample: n = 44		Success: 100 %		
E2 and S2 (0) not specified	>>>	44	Not specified	100 %
Total per sample: n = 44		Success: 100 %		
Total success: 100 %				

(705) Rh D antigen (blood-donor)

E1 and S1 (6) APR		1	Negative (RhD-)	1,3 %
	>>>	1	w/v (RhD weak/variant)	1,3 %
(14) Bio-Rad	>	4	Positive (RhD+)	5,3 %
	>>>	17	w/v (RhD weak/variant)	22 %
(40) Ortho Clinical Diagnostics	>>>	1	w/v (RhD weak/variant)	1,3 %
(52) Dynex	>>>	1	w/v (RhD weak/variant)	1,3 %
(64) Exbio Olomouc	>>>	2	w/v (RhD weak/variant)	2,6 %
(80) DiaMed		1	Negative (RhD-)	1,3 %
	>>>	6	w/v (RhD weak/variant)	7,9 %
(159) Grifols		2	Negative (RhD-)	2,6 %
	>	4	Positive (RhD+)	5,3 %
	>>>	10	w/v (RhD weak/variant)	13 %
(172) Immucor	>	4	Positive (RhD+)	5,3 %
	>>>	12	w/v (RhD weak/variant)	16 %
(173) Sanguin	>>>	4	w/v (RhD weak/variant)	5,3 %
(174) IVT Imuno	>>>	3	w/v (RhD weak/variant)	3,9 %
(203) ANTITOXIN	>>>	1	w/v (RhD weak/variant)	1,3 %
(999) another manufacturer	>	1	Positive (RhD+)	1,3 %
	>>>	1	w/v (RhD weak/variant)	1,3 %
Total per sample: n = 76		Success: 95 %		
E2 and S2 (6) APR	>>>	2	Positive (RhD+)	2,6 %
(14) Bio-Rad	>>>	21	Positive (RhD+)	28 %
(40) Ortho Clinical Diagnostics	>>>	1	Positive (RhD+)	1,3 %
(52) Dynex	>>>	1	Positive (RhD+)	1,3 %
(64) Exbio Olomouc	>>>	2	Positive (RhD+)	2,6 %
(80) DiaMed	>>>	7	Positive (RhD+)	9,2 %
(159) Grifols	>>>	15	Positive (RhD+)	20 %
		1	w/v (RhD weak/variant)	1,3 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH2/21 - Blood Group Serology

Deadline: 04.06.2021

Test	Sample	Group	N	Result	N _{rel}
E2 and S2	(172)	Immucor	>>> 16	Positive (RhD+)	21 %
	(173)	Sanguin	>>> 4	Positive (RhD+)	5,3 %
	(174)	IVT Imuno	>>> 3	Positive (RhD+)	3,9 %
	(203)	ANTITOXIN	>>> 1	Positive (RhD+)	1,3 %
	(999)	another manufacturer	>>> 2	Positive (RhD+)	2,6 %
	Total per sample: n = 76			Success: 99 %	
Total success: 93 %					

(709) Rh D antigen (recipient)

E1 and S1	(0) not specified	>	3	Negative (RhD-)	2,2 %
	(6) APR	>	2	Negative (RhD-)	1,5 %
		>>>	1	w/v (RhD weak/variant)	0,74 %
	(14) Bio-Rad	>	13	Negative (RhD-)	9,6 %
		>>>	27	w/v (RhD weak/variant)	20 %
	(40) Ortho Clinical Diagnostics	>>>	2	w/v (RhD weak/variant)	1,5 %
	(50) Merck	>	1	Negative (RhD-)	0,74 %
	(52) Dynex	>>>	2	w/v (RhD weak/variant)	1,5 %
	(64) Exbio Olomouc	>	5	Negative (RhD-)	3,7 %
		>>>	1	w/v (RhD weak/variant)	0,74 %
	(80) DiaMed	>	6	Negative (RhD-)	4,4 %
		>	1	Positive (RhD+)	0,74 %
		>>>	6	w/v (RhD weak/variant)	4,4 %
	(159) Grifols	>	9	Negative (RhD-)	6,7 %
		>	2	Positive (RhD+)	1,5 %
		>>>	19	w/v (RhD weak/variant)	14 %
	(172) Immucor	>	1	Not specified	0,74 %
		>	11	Negative (RhD-)	8,1 %
		>	1	Positive (RhD+)	0,74 %
		>>>	5	w/v (RhD weak/variant)	3,7 %
	(173) Sanguin	>	3	Negative (RhD-)	2,2 %
		>	1	Positive (RhD+)	0,74 %
		>>>	1	w/v (RhD weak/variant)	0,74 %
	(174) IVT Imuno	>	3	Negative (RhD-)	2,2 %
		>>>	3	w/v (RhD weak/variant)	2,2 %
	(203) ANTITOXIN	>>>	1	w/v (RhD weak/variant)	0,74 %
	(999) another manufacturer	>	4	Negative (RhD-)	3,0 %
	>>>	1	w/v (RhD weak/variant)	0,74 %	
Total per sample: n = 135			Success: 96 %		
E2 and S2	(0) not specified	>>>	3	Positive (RhD+)	2,2 %
	(6) APR	>>>	3	Positive (RhD+)	2,2 %
	(14) Bio-Rad	>>>	40	Positive (RhD+)	30 %
	(40) Ortho Clinical Diagnostics	>>>	2	Positive (RhD+)	1,5 %
	(50) Merck	>>>	1	Positive (RhD+)	0,74 %
	(52) Dynex	>>>	2	Positive (RhD+)	1,5 %
	(64) Exbio Olomouc	>>>	6	Positive (RhD+)	4,4 %
	(80) DiaMed	>>>	13	Positive (RhD+)	9,6 %
	(159) Grifols	>>>	30	Positive (RhD+)	22 %
	(172) Immucor	>>>	18	Positive (RhD+)	13 %
	(173) Sanguin	>>>	5	Positive (RhD+)	3,7 %
	(174) IVT Imuno	>>>	6	Positive (RhD+)	4,4 %
	(203) ANTITOXIN	>>>	1	Positive (RhD+)	0,74 %
	(999) another manufacturer	>>>	5	Positive (RhD+)	3,7 %
	Total per sample: n = 135			Success: 100 %	
Total success: 96 %					

(715) Antigen C

E1 and S1	(6) APR	>>>	1	Positive	1,6 %
	(14) Bio-Rad	>>>	24	Positive	38 %
	(64) Exbio Olomouc	>>>	1	Positive	1,6 %
	(80) DiaMed	>>>	6	Positive	9,4 %
	(159) Grifols	>>>	14	Positive	22 %
	(172) Immucor	>>>	11	Positive	17 %
	(173) Sanguin	>>>	2	Positive	3,1 %
	(174) IVT Imuno	>>>	2	Positive	3,1 %
	(203) ANTITOXIN	>>>	2	Positive	3,1 %
	(999) another manufacturer	>>>	1	Positive	1,6 %
	Total per sample: n = 64			Success: 100 %	
E2 and S2	(6) APR	>>>	1	Negative	1,6 %
	(14) Bio-Rad	>>>	24	Negative	38 %
	(64) Exbio Olomouc	>>>	1	Negative	1,6 %
	(80) DiaMed	>>>	6	Negative	9,4 %

EQA round: IH2/21 - Blood Group Serology

Deadline: 04.06.2021

Test		N	Result	N _{rel}
Sample	Group			
E2 and S2 (159)	Grifols	>>> 14	Negative	22 %
(172)	Immucor	>>> 11	Negative	17 %
(173)	Sanguin	>>> 2	Negative	3,1 %
(174)	IVT Imuno	>>> 2	Negative	3,1 %
(203)	ANTITOXIN	>>> 2	Negative	3,1 %
(999)	another manufacturer	>>> 1	Negative	1,6 %
Total per sample: n = 64		Success: 100 %		

Total success: 100 %

(716) Antigen c

E1 and S1 (6)	APR	>>> 1	Positive	1,6 %
(14)	Bio-Rad	>>> 24	Positive	38 %
(64)	Exbio Olomouc	>>> 1	Negative	1,6 %
(80)	DiaMed	>>> 6	Positive	9,4 %
(159)	Grifols	>>> 14	Positive	22 %
(172)	Immucor	>>> 11	Positive	17 %
(173)	Sanguin	>>> 2	Positive	3,1 %
(174)	IVT Imuno	>>> 2	Positive	3,1 %
(203)	ANTITOXIN	>>> 2	Positive	3,1 %
(999)	another manufacturer	>>> 1	Positive	1,6 %
Total per sample: n = 64		Success: 98 %		

E2 and S2 (6)	APR	>>> 1	Positive	1,6 %
(14)	Bio-Rad	>>> 24	Positive	38 %
(64)	Exbio Olomouc	>>> 1	Positive	1,6 %
(80)	DiaMed	>>> 6	Positive	9,4 %
(159)	Grifols	>>> 14	Positive	22 %
(172)	Immucor	>>> 11	Positive	17 %
(173)	Sanguin	>>> 2	Positive	3,1 %
(174)	IVT Imuno	>>> 2	Positive	3,1 %
(203)	ANTITOXIN	>>> 2	Positive	3,1 %
(999)	another manufacturer	>>> 1	Positive	1,6 %
Total per sample: n = 64		Success: 100 %		

Total success: 98 %

(717) Antigen Cw

E1 and S1 (6)	APR	>>> 1	Negative	1,8 %
(14)	Bio-Rad	>>> 18	Negative	33 %
(52)	Dynex	>>> 1	Negative	1,8 %
(64)	Exbio Olomouc	>>> 1	Negative	1,8 %
(80)	DiaMed	>>> 2	Negative	3,6 %
(159)	Grifols	>>> 14	Negative	25 %
(172)	Immucor	>>> 11	Negative	20 %
(173)	Sanguin	>>> 4	Negative	7,3 %
(174)	IVT Imuno	>>> 1	Negative	1,8 %
(203)	ANTITOXIN	>>> 2	Negative	3,6 %
Total per sample: n = 55		Success: 100 %		

E2 and S2 (6)	APR	>>> 1	Negative	1,8 %
(14)	Bio-Rad	>>> 18	Negative	33 %
(52)	Dynex	>>> 1	Negative	1,8 %
(64)	Exbio Olomouc	>>> 1	Negative	1,8 %
(80)	DiaMed	>>> 2	Negative	3,6 %
(159)	Grifols	>>> 14	Negative	25 %
(172)	Immucor	>>> 11	Negative	20 %
(173)	Sanguin	>>> 4	Negative	7,3 %
(174)	IVT Imuno	>>> 1	Negative	1,8 %
(203)	ANTITOXIN	>>> 2	Negative	3,6 %
Total per sample: n = 55		Success: 100 %		

Total success: 100 %

(718) Antigen E

E1 and S1 (6)	APR	>>> 1	Negative	1,6 %
(14)	Bio-Rad	>>> 24	Negative	38 %
(64)	Exbio Olomouc	>>> 1	Negative	1,6 %
(80)	DiaMed	>>> 6	Negative	9,4 %
(159)	Grifols	>>> 14	Negative	22 %
(172)	Immucor	>>> 11	Negative	17 %
(173)	Sanguin	>>> 2	Negative	3,1 %
(174)	IVT Imuno	>>> 2	Negative	3,1 %
(203)	ANTITOXIN	>>> 2	Negative	3,1 %
(999)	another manufacturer	>>> 1	Negative	1,6 %

Test

Sample	Group	N	Result	N _{rel}
Total per sample: n = 64		Success: 100 %		
E2 and S2 (6) APR		>>> 1	Positive	1,6 %
(14) Bio-Rad		>>> 24	Positive	38 %
(64) Exbio Olomouc		>>> 1	Positive	1,6 %
(80) DiaMed		>>> 6	Positive	9,4 %
(159) Grifols		>>> 14	Positive	22 %
(172) Immucor		>>> 11	Positive	17 %
(173) Sanguin		>>> 2	Positive	3,1 %
(174) IVT Imuno		>>> 2	Positive	3,1 %
(203) ANTITOXIN		>>> 2	Positive	3,1 %
(999) another manufacturer		>>> 1	Positive	1,6 %
Total per sample: n = 64		Success: 100 %		
Total success: 100 %				

(719) Antigen e

E1 and S1 (6) APR		>>> 1	Positive	1,6 %
(14) Bio-Rad		>>> 24	Positive	38 %
(64) Exbio Olomouc		>>> 1	Positive	1,6 %
(80) DiaMed		>>> 6	Positive	9,4 %
(159) Grifols		>>> 14	Positive	22 %
(172) Immucor		>>> 11	Positive	17 %
(173) Sanguin		>>> 2	Positive	3,1 %
(174) IVT Imuno		>>> 2	Positive	3,1 %
(203) ANTITOXIN		>>> 2	Positive	3,1 %
(999) another manufacturer		>>> 1	Positive	1,6 %
Total per sample: n = 64		Success: 100 %		
E2 and S2 (6) APR		>>> 1	Negative	1,6 %
(14) Bio-Rad		>>> 24	Negative	38 %
(64) Exbio Olomouc		>>> 1	Negative	1,6 %
(80) DiaMed		>>> 6	Negative	9,4 %
(159) Grifols		>>> 14	Negative	22 %
(172) Immucor		>>> 11	Negative	17 %
(173) Sanguin		>>> 2	Negative	3,1 %
(174) IVT Imuno		>>> 2	Negative	3,1 %
(203) ANTITOXIN		>>> 2	Negative	3,1 %
(999) another manufacturer		>>> 1	Negative	1,6 %
Total per sample: n = 64		Success: 100 %		
Total success: 100 %				

(720) Antigen K

E1 and S1 (6) APR		>>> 1	Positive	1,5 %
(14) Bio-Rad		>>> 21	Positive	31 %
(80) DiaMed		>>> 6	Positive	9,0 %
(159) Grifols		>>> 18	Positive	27 %
(172) Immucor		>>> 11	Positive	16 %
(173) Sanguin		>>> 3	Positive	4,5 %
(174) IVT Imuno		>>> 1	Negative	1,5 %
		>>> 3	Positive	4,5 %
(203) ANTITOXIN		>>> 1	Positive	1,5 %
(999) another manufacturer		>>> 2	Positive	3,0 %
Total per sample: n = 67		Success: 99 %		
E2 and S2 (6) APR		>>> 1	Negative	1,5 %
(14) Bio-Rad		>>> 21	Negative	31 %
(80) DiaMed		>>> 6	Negative	9,0 %
(159) Grifols		>>> 18	Negative	27 %
(172) Immucor		>>> 11	Negative	16 %
(173) Sanguin		>>> 3	Negative	4,5 %
(174) IVT Imuno		>>> 4	Negative	6,0 %
(203) ANTITOXIN		>>> 1	Negative	1,5 %
(999) another manufacturer		>>> 2	Negative	3,0 %
Total per sample: n = 67		Success: 100 %		
Total success: 99 %				

(721) Antigen k

E1 and S1 (0) not specified		>>> 2	Positive	4,8 %
(6) APR		>>> 1	Positive	2,4 %
(14) Bio-Rad		>>> 11	Positive	26 %
(64) Exbio Olomouc		>>> 5	Positive	12 %
(80) DiaMed		>>> 1	Positive	2,4 %
(159) Grifols		>>> 5	Positive	12 %
(172) Immucor		>>> 5	Positive	12 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH2/21 - Blood Group Serology

Deadline: 04.06.2021

Test		N	Result	N _{rel}
Sample	Group			
E1 and S1 (173)	Sanguin	>>> 8	Positive	19 %
	(203) ANTITOXIN	>>> 3	Positive	7,1 %
	(999) another manufacturer	>>> 1	Positive	2,4 %
----- Total per sample: n = 42 -----		Success: 100 %		
E2 and S2 (0)	not specified	2	Not specified	4,8 %
	(6) APR	>>> 1	Positive	2,4 %
	(14) Bio-Rad	1	Not specified	2,4 %
		>>> 10	Positive	24 %
	(64) Exbio Olomouc	>>> 5	Positive	12 %
	(80) DiaMed	>>> 1	Positive	2,4 %
	(159) Grifols	>>> 5	Positive	12 %
	(172) Immucor	1	Not specified	2,4 %
		>>> 4	Positive	9,5 %
	(173) Sanguin	>>> 8	Positive	19 %
	(203) ANTITOXIN	>>> 3	Positive	7,1 %
	(999) another manufacturer	>>> 1	Positive	2,4 %
----- Total per sample: n = 42 -----		Success: 90 %		
Total success: 90 %				

(722) Antigen M

E1 and S1 (14)	Bio-Rad	>>> 9	Positive	26 %
	(64) Exbio Olomouc	>>> 3	Positive	8,6 %
	(80) DiaMed	>>> 3	Positive	8,6 %
	(159) Grifols	>>> 3	Positive	8,6 %
	(172) Immucor	>>> 13	Positive	37 %
	(173) Sanguin	>>> 2	Positive	5,7 %
	(203) ANTITOXIN	>>> 2	Positive	5,7 %
----- Total per sample: n = 35 -----		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>> 9	Positive	26 %
	(64) Exbio Olomouc	>>> 3	Positive	8,6 %
	(80) DiaMed	>>> 3	Positive	8,6 %
	(159) Grifols	>>> 3	Positive	8,6 %
	(172) Immucor	>>> 13	Positive	37 %
	(173) Sanguin	>>> 2	Positive	5,7 %
	(203) ANTITOXIN	>>> 2	Positive	5,7 %
----- Total per sample: n = 35 -----		Success: 100 %		
Total success: 100 %				

(723) Antigen N

E1 and S1 (14)	Bio-Rad	>>> 9	Negative	29 %
	(64) Exbio Olomouc	>>> 2	Negative	6,5 %
	(80) DiaMed	>>> 3	Negative	9,7 %
	(159) Grifols	>>> 3	Negative	9,7 %
	(172) Immucor	>>> 10	Negative	32 %
	(173) Sanguin	>>> 2	Negative	6,5 %
	(203) ANTITOXIN	>>> 1	Negative	3,2 %
		1	Positive	3,2 %
----- Total per sample: n = 31 -----		Success: 97 %		
E2 and S2 (14)	Bio-Rad	>>> 9	Positive	29 %
	(64) Exbio Olomouc	>>> 2	Positive	6,5 %
	(80) DiaMed	>>> 3	Positive	9,7 %
	(159) Grifols	>>> 3	Positive	9,7 %
	(172) Immucor	>>> 10	Positive	32 %
	(173) Sanguin	>>> 2	Positive	6,5 %
	(203) ANTITOXIN	>>> 2	Positive	6,5 %
----- Total per sample: n = 31 -----		Success: 100 %		
Total success: 97 %				

(724) Antigen S

E1 and S1 (14)	Bio-Rad	>>> 10	Positive	28 %
	(50) Merck	>>> 1	Positive	2,8 %
	(52) Dynex	>>> 2	Positive	5,6 %
	(64) Exbio Olomouc	>>> 2	Positive	5,6 %
	(80) DiaMed	>>> 3	Positive	8,3 %
	(159) Grifols	>>> 4	Positive	11 %
	(172) Immucor	>>> 6	Positive	17 %
	(173) Sanguin	>>> 4	Positive	11 %
	(174) IVT Imuno	>>> 2	Positive	5,6 %
	(203) ANTITOXIN	>>> 2	Positive	5,6 %
----- Total per sample: n = 36 -----		Success: 100 %		

Test			N	Result	N _{rel}
Sample	Group				
E2 and S2	(14) Bio-Rad	>>>	10	Negative	28 %
	(50) Merck	>>>	1	Negative	2,8 %
	(52) Dynex	>>>	2	Negative	5,6 %
	(64) Exbio Olomouc	>>>	2	Negative	5,6 %
	(80) DiaMed	>>>	3	Negative	8,3 %
	(159) Grifols	>>>	4	Negative	11 %
	(172) Immucor	>>>	6	Negative	17 %
	(173) Sanguin	>>>	4	Negative	11 %
	(174) IVT Imuno	>>>	2	Negative	5,6 %
	(203) ANTITOXIN	>>>	2	Negative	5,6 %
Total per sample: n = 36		Success: 100 %			
Total success: 100 %					

(725) Antigen s

E1 and S1	(14) Bio-Rad	>>>	9	Positive	26 %
	(52) Dynex	>>>	1	Positive	2,9 %
	(64) Exbio Olomouc	>>>	3	Positive	8,6 %
	(80) DiaMed	>>>	3	Positive	8,6 %
	(159) Grifols	>>>	4	Positive	11 %
	(172) Immucor	>>>	6	Positive	17 %
	(173) Sanguin	>>>	5	Positive	14 %
	(174) IVT Imuno	>>>	2	Positive	5,7 %
	(203) ANTITOXIN	>>>	2	Positive	5,7 %
Total per sample: n = 35		Success: 100 %			
E2 and S2	(14) Bio-Rad	>>>	9	Positive	26 %
	(52) Dynex	>>>	1	Positive	2,9 %
	(64) Exbio Olomouc	>>>	3	Positive	8,6 %
	(80) DiaMed	>>>	3	Positive	8,6 %
	(159) Grifols	>>>	4	Positive	11 %
	(172) Immucor	>>>	6	Positive	17 %
	(173) Sanguin	>>>	5	Positive	14 %
	(174) IVT Imuno	>>>	2	Positive	5,7 %
	(203) ANTITOXIN	>>>	2	Positive	5,7 %
Total per sample: n = 35		Success: 100 %			
Total success: 100 %					

(726) Antigen P1

E1 and S1	(14) Bio-Rad	>>>	6	Positive	23 %
	(64) Exbio Olomouc	>>>	2	Positive	7,7 %
	(80) DiaMed	>>>	2	Positive	7,7 %
	(159) Grifols	>>>	1	Positive	3,8 %
	(172) Immucor	>>>	8	Positive	31 %
	(173) Sanguin	>>>	5	Positive	19 %
	(174) IVT Imuno	>>>	1	Positive	3,8 %
	(203) ANTITOXIN	>>>	1	Positive	3,8 %
Total per sample: n = 26		Success: 100 %			
E2 and S2	(14) Bio-Rad	>>>	6	Negative	23 %
	(64) Exbio Olomouc	>>>	2	Negative	7,7 %
	(80) DiaMed	>>>	2	Negative	7,7 %
	(159) Grifols	>>>	1	Negative	3,8 %
	(172) Immucor	>>>	8	Negative	31 %
	(173) Sanguin	>>>	5	Negative	19 %
	(174) IVT Imuno	>>>	1	Negative	3,8 %
	(203) ANTITOXIN	>>>	1	Negative	3,8 %
Total per sample: n = 26		Success: 100 %			
Total success: 100 %					

(727) Antigen Fya

E1 and S1	(14) Bio-Rad	>>>	11	Positive	31 %
	(64) Exbio Olomouc	>>>	3	Positive	8,3 %
	(80) DiaMed	>>>	3	Positive	8,3 %
	(159) Grifols	>>>	5	Positive	14 %
	(172) Immucor	>>>	6	Positive	17 %
	(173) Sanguin	>>>	5	Positive	14 %
	(174) IVT Imuno	>>>	1	Positive	2,8 %
	(203) ANTITOXIN	>>>	2	Positive	5,6 %
Total per sample: n = 36		Success: 100 %			
E2 and S2	(14) Bio-Rad	>>>	11	Negative	31 %
	(64) Exbio Olomouc	>>>	3	Negative	8,3 %
	(80) DiaMed	>>>	3	Negative	8,3 %

EQA round: IH2/21 - Blood Group Serology

Deadline: 04.06.2021

Test

Sample	Group	N	Result	N _{rel}
E2 and S2 (159)	Grifols	>>>	5 Negative	14 %
(172)	Immucor	>>>	6 Negative	17 %
(173)	Sanguin	>>>	5 Negative	14 %
(174)	IVT Imuno	>>>	1 Negative	2,8 %
(203)	ANTITOXIN	>>>	2 Negative	5,6 %
Total per sample: n = 36		Success: 100 %		
Total success: 100 %				

(728) Antigen Fyb

E1 and S1 (14)	Bio-Rad	>>>	11 Positive	31 %
(64)	Exbio Olomouc	>>>	3 Positive	8,3 %
(80)	DiaMed	>>>	3 Positive	8,3 %
(159)	Grifols	>>>	5 Positive	14 %
(172)	Immucor	>>>	6 Positive	17 %
(173)	Sanguin	>>>	5 Positive	14 %
(174)	IVT Imuno	>>>	1 Positive	2,8 %
(203)	ANTITOXIN	>>>	2 Positive	5,6 %
Total per sample: n = 36		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>>	11 Positive	31 %
(64)	Exbio Olomouc	>>>	3 Positive	8,3 %
(80)	DiaMed	>>>	3 Positive	8,3 %
(159)	Grifols	>>>	5 Positive	14 %
(172)	Immucor	>>>	6 Positive	17 %
(173)	Sanguin	>>>	5 Positive	14 %
(174)	IVT Imuno	>>>	1 Positive	2,8 %
(203)	ANTITOXIN	>>>	2 Positive	5,6 %
Total per sample: n = 36		Success: 100 %		
Total success: 100 %				

(729) Antigen Jka

E1 and S1 (14)	Bio-Rad	>>>	11 Positive	30 %
(50)	Merck	>>>	1 Positive	2,7 %
(52)	Dynex	>>>	2 Positive	5,4 %
(64)	Exbio Olomouc	>>>	2 Positive	5,4 %
(80)	DiaMed	>>>	3 Positive	8,1 %
(159)	Grifols	>>>	5 Positive	14 %
(172)	Immucor	>>>	6 Positive	16 %
(173)	Sanguin	>>>	5 Positive	14 %
(203)	ANTITOXIN	>>>	2 Positive	5,4 %
Total per sample: n = 37		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>>	11 Positive	30 %
(50)	Merck	>>>	1 Positive	2,7 %
(52)	Dynex	>>>	2 Positive	5,4 %
(64)	Exbio Olomouc	>>>	2 Positive	5,4 %
(80)	DiaMed	>>>	3 Positive	8,1 %
(159)	Grifols	>>>	5 Positive	14 %
(172)	Immucor	>>>	6 Positive	16 %
(173)	Sanguin	>>>	5 Positive	14 %
(203)	ANTITOXIN	>>>	2 Positive	5,4 %
Total per sample: n = 37		Success: 100 %		
Total success: 100 %				

(730) Antigen Jkb

E1 and S1 (14)	Bio-Rad	>>>	11 Positive	30 %
(50)	Merck	>>>	1 Positive	2,7 %
(52)	Dynex	>>>	2 Positive	5,4 %
(64)	Exbio Olomouc	>>>	2 Positive	5,4 %
(80)	DiaMed	>>>	3 Positive	8,1 %
(159)	Grifols	>>>	5 Positive	14 %
(172)	Immucor	>>>	6 Positive	16 %
(173)	Sanguin	>>>	5 Positive	14 %
(203)	ANTITOXIN	>>>	2 Positive	5,4 %
Total per sample: n = 37		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>>	11 Positive	30 %
(50)	Merck	>>>	1 Positive	2,7 %
(52)	Dynex	>>>	2 Positive	5,4 %
(64)	Exbio Olomouc	>>>	2 Positive	5,4 %
(80)	DiaMed	>>>	3 Positive	8,1 %
(159)	Grifols	>>>	5 Positive	14 %
(172)	Immucor	>>>	6 Positive	16 %

Test		N	Result	N _{rel}
Sample	Group			
E2 and S2 (173)	Sanguin	>>> 5	Positive	14 %
(203)	ANTITOXIN	>>> 2	Positive	5,4 %
Total per sample: n = 37		Success: 100 %		
Total success: 100 %				
(731) Antigen Lua				
E1 and S1 (14)	Bio-Rad	>>> 10	Negative	40 %
(64)	Exbio Olomouc	>>> 1	Negative	4,0 %
(80)	DiaMed	>>> 2	Negative	8,0 %
(159)	Grifols	>>> 6	Negative	24 %
(172)	Immucor	>>> 4	Negative	16 %
(173)	Sanguin	>>> 1	Negative	4,0 %
(203)	ANTITOXIN	>>> 1	Negative	4,0 %
Total per sample: n = 25		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>> 10	Negative	40 %
(64)	Exbio Olomouc	>>> 1	Negative	4,0 %
(80)	DiaMed	>>> 2	Negative	8,0 %
(159)	Grifols	>>> 6	Negative	24 %
(172)	Immucor	>>> 4	Negative	16 %
(173)	Sanguin	>>> 1	Negative	4,0 %
(203)	ANTITOXIN	>>> 1	Negative	4,0 %
Total per sample: n = 25		Success: 100 %		
Total success: 100 %				
(732) Antigen Lub				
E1 and S1 (14)	Bio-Rad	>>> 8	Positive	32 %
(64)	Exbio Olomouc	>>> 1	Positive	4,0 %
(80)	DiaMed	>>> 2	Positive	8,0 %
(159)	Grifols	>>> 5	Positive	20 %
(172)	Immucor	>>> 4	Positive	16 %
(173)	Sanguin	>>> 1	Positive	4,0 %
(203)	ANTITOXIN	>>> 2	Positive	8,0 %
(999)	another manufacturer	>>> 2	Positive	8,0 %
Total per sample: n = 25		Success: 100 %		
E2 and S2 (14)	Bio-Rad	>>> 8	Positive	32 %
(64)	Exbio Olomouc	>>> 1	Positive	4,0 %
(80)	DiaMed	>>> 2	Positive	8,0 %
(159)	Grifols	>>> 5	Positive	20 %
(172)	Immucor	>>> 4	Positive	16 %
(173)	Sanguin	>>> 1	Positive	4,0 %
(203)	ANTITOXIN	>>> 2	Positive	8,0 %
(999)	another manufacturer	>>> 2	Positive	8,0 %
Total per sample: n = 25		Success: 100 %		
Total success: 100 %				
(733) Antigen Lea				
E1 and S1 (14)	Bio-Rad	>>> 8	Negative	26 %
		>>> 1	Positive	3,2 %
(50)	Merck	>>> 1	Negative	3,2 %
(64)	Exbio Olomouc	>>> 1	Negative	3,2 %
(80)	DiaMed	>>> 3	Negative	9,7 %
(159)	Grifols	>>> 3	Negative	9,7 %
(172)	Immucor	>>> 9	Negative	29 %
(173)	Sanguin	>>> 1	Negative	3,2 %
(174)	IVT Imuno	>>> 2	Negative	6,5 %
(203)	ANTITOXIN	>>> 2	Negative	6,5 %
Total per sample: n = 31		Success: 97 %		
E2 and S2 (14)	Bio-Rad	>>> 9	Negative	29 %
(50)	Merck	>>> 1	Negative	3,2 %
(64)	Exbio Olomouc	>>> 1	Negative	3,2 %
(80)	DiaMed	>>> 3	Negative	9,7 %
(159)	Grifols	>>> 3	Negative	9,7 %
(172)	Immucor	>>> 9	Negative	29 %
(173)	Sanguin	>>> 1	Negative	3,2 %
(174)	IVT Imuno	>>> 2	Negative	6,5 %
(203)	ANTITOXIN	>>> 2	Negative	6,5 %
Total per sample: n = 31		Success: 100 %		
Total success: 97 %				
(734) Antigen Leb				
E1 and S1 (14)	Bio-Rad	2	Negative	6,5 %

EQA round: IH2/21 - Blood Group Serology

Deadline: 04.06.2021

Test

Sample	Group	N	Result	N _{rel}
E1 and S1 (14)	Bio-Rad	>>>	7 Positive	23 %
	(50) Merck	>>>	1 Positive	3,2 %
	(64) Exbio Olomouc	>>>	1 Positive	3,2 %
	(80) DiaMed	>>>	3 Positive	9,7 %
	(159) Grifols	>>>	3 Positive	9,7 %
	(172) Immucor	>>>	9 Positive	29 %
	(173) Sanguin	>>>	1 Positive	3,2 %
	(174) IVT Imuno	>>>	1 Negative	3,2 %
		>>>	1 Positive	3,2 %
	(203) ANTITOXIN	>>>	2 Positive	6,5 %
Total per sample: n = 31		Success: 90 %		
E2 and S2 (14)	Bio-Rad	>>>	9 Negative	29 %
	(50) Merck	>>>	1 Negative	3,2 %
	(64) Exbio Olomouc	>>>	1 Negative	3,2 %
	(80) DiaMed	>>>	3 Negative	9,7 %
	(159) Grifols	>>>	3 Negative	9,7 %
	(172) Immucor	>>>	9 Negative	29 %
	(173) Sanguin	>>>	1 Negative	3,2 %
	(174) IVT Imuno	>>>	2 Negative	6,5 %
	(203) ANTITOXIN	>>>	2 Negative	6,5 %
	Total per sample: n = 31		Success: 100 %	

Total success: 90 %

(737) Direct Coombs (antiglobulin) test

E1 and S1 (6)	APR	>>>	1 Negative	0,85 %
	(14) Bio-Rad	>>>	50 Negative	43 %
	(40) Ortho Clinical Diagnostics	>>>	2 Negative	1,7 %
	(64) Exbio Olomouc	>>>	2 Negative	1,7 %
	(80) DiaMed	>>>	25 Negative	21 %
	(159) Grifols	>>>	35 Negative	30 %
	(173) Sanguin	>>>	1 Negative	0,85 %
	(174) IVT Imuno	>>>	1 Negative	0,85 %
Total per sample: n = 117		Success: 100 %		
E2 and S2 (6)	APR	>>>	1 Negative	0,85 %
	(14) Bio-Rad	>>>	50 Negative	43 %
	(40) Ortho Clinical Diagnostics	>>>	2 Negative	1,7 %
	(64) Exbio Olomouc	>>>	2 Negative	1,7 %
	(80) DiaMed	>>>	25 Negative	21 %
	(159) Grifols	>>>	35 Negative	30 %
	(173) Sanguin	>>>	1 Negative	0,85 %
	(174) IVT Imuno	>>>	1 Negative	0,85 %
Total per sample: n = 117		Success: 100 %		

Total success: 100 %

(741) Antibody screening (IAT, blood donor)

E1 and S1 (6)	APR	>>>	2 Positive	2,9 %
	(14) Bio-Rad	>>>	26 Positive	37 %
	(40) Ortho Clinical Diagnostics	>>>	1 Positive	1,4 %
	(64) Exbio Olomouc	>>>	1 Positive	1,4 %
	(80) DiaMed	>>>	14 Positive	20 %
	(159) Grifols	>>>	16 Positive	23 %
	(172) Immucor	>>>	10 Positive	14 %
Total per sample: n = 70		Success: 100 %		
E2 and S2 (6)	APR	>>>	2 Positive	2,9 %
	(14) Bio-Rad	>>>	26 Positive	37 %
	(40) Ortho Clinical Diagnostics	>>>	1 Positive	1,4 %
	(64) Exbio Olomouc	>>>	1 Positive	1,4 %
	(80) DiaMed	>>>	14 Positive	20 %
	(159) Grifols	>>>	16 Positive	23 %
	(172) Immucor	>>>	10 Positive	14 %
Total per sample: n = 70		Success: 100 %		

Total success: 100 %

(743) Antibody screening (IAT, recipient)

E1 and S1 (0)	not specified	>>>	1 Positive	0,79 %
	(6) APR	>>>	2 Positive	1,6 %
	(14) Bio-Rad	>>>	57 Positive	45 %
	(40) Ortho Clinical Diagnostics	>>>	2 Positive	1,6 %
	(80) DiaMed	>>>	26 Positive	20 %
	(159) Grifols	>>>	34 Positive	27 %

Test

Sample	Group	N	Result	N _{rel}
E1 and S1 (172) Immucor	>>>	5	Positive	3,9 %
----- Total per sample: n = 127 ----- Success: 100 % -----				
E2 and S2 (0) not specified	>>>	1	Positive	0,79 %
(6) APR	>>>	2	Positive	1,6 %
(14) Bio-Rad	>>>	57	Positive	45 %
(40) Ortho Clinical Diagnostics	>>>	2	Positive	1,6 %
(80) DiaMed	>>>	26	Positive	20 %
(159) Grifols	>>>	34	Positive	27 %
(172) Immucor	>>>	5	Positive	3,9 %
----- Total per sample: n = 127 ----- Success: 100 % -----				
Total success: 100 %				

(745) Antibody screening (IAT, pregnant)

E1 and S1 (6) APR	>>>	2	Positive	1,9 %
(14) Bio-Rad	>>>	45	Positive	43 %
(40) Ortho Clinical Diagnostics	>>>	2	Positive	1,9 %
(64) Exbio Olomouc	>>>	1	Positive	0,96 %
(80) DiaMed	>>>	19	Positive	18 %
(159) Grifols	>>>	31	Positive	30 %
(172) Immucor	>>>	4	Positive	3,8 %
----- Total per sample: n = 104 ----- Success: 100 % -----				
E2 and S2 (6) APR	>>>	2	Positive	1,9 %
(14) Bio-Rad	>>>	45	Positive	43 %
(40) Ortho Clinical Diagnostics	>>>	2	Positive	1,9 %
(64) Exbio Olomouc	>>>	1	Positive	0,96 %
(80) DiaMed	>>>	19	Positive	18 %
(159) Grifols	>>>	31	Positive	30 %
(172) Immucor	>>>	4	Positive	3,8 %
----- Total per sample: n = 104 ----- Success: 100 % -----				
Total success: 100 %				

(747) Antibody screening (enzyme test)

E1 and S1 (0) not specified	>>>	1	Positive	1,0 %
(14) Bio-Rad		1	Not specified	1,0 %
	>>>	45	Positive	47 %
(40) Ortho Clinical Diagnostics	>>>	2	Positive	2,1 %
(80) DiaMed	>>>	20	Positive	21 %
(159) Grifols	>>>	26	Positive	27 %
(172) Immucor	>>>	1	Positive	1,0 %
----- Total per sample: n = 96 ----- Success: 99 % -----				
E2 and S2 (0) not specified	>>>	1	Positive	1,0 %
(14) Bio-Rad	>>>	46	Positive	48 %
(40) Ortho Clinical Diagnostics	>>>	2	Positive	2,1 %
(80) DiaMed	>>>	20	Positive	21 %
(159) Grifols	>>>	26	Positive	27 %
(172) Immucor	>>>	1	Positive	1,0 %
----- Total per sample: n = 96 ----- Success: 100 % -----				
Total success: 99 %				

(750) Antibody identification

E1 and S1 (0) not specified	>>>	43	anti-E	100 %
----- Total per sample: n = 43 ----- Success: 100 % -----				
E2 and S2 (0) not specified	>	16	anti-e	37 %
	>>>	27	anti-e; anti-C	63 %
----- Total per sample: n = 43 ----- Success: 100 % -----				
Total success: 100 %				

(752) Antibody titre, Sample 1: 1st antibody

E1 and S1 (0) not specified	±	1	titre 4	3,2 %
	±	10	titre 8	32 %
	±	12	titre 16	39 %
	±	7	titre 32	23 %
	±	1	titre 64	3,2 %
----- Total per sample: n = 31 ----- Success (only evaluated results): evaluation -----				

(756) Antibody titre, Sample 2: 1st antibody

E2 and S2 (0) not specified	±	6	titre 1	21 %
	±	4	titre 2	14 %
	±	7	titre 4	24 %
	±	6	titre 8	21 %
	±	3	titre 16	10 %
	±	1	titre 32	3,4 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IH2/21 - Blood Group Serology

Deadline: 04.06.2021

Test	Sample	Group	N	Result	N _{rel}
	E2 and S2 (0) not specified		± 2	titre 64	6,9 %
	Total per sample: n = 29		Success (only evaluated results): evaluation		

(757) Antibody titre, Sample 2: 2nd antibody

E2 and S2 (0) not specified	± 1	titre 0 (not measurable)	6,3 %
	± 1	titre 2	6,3 %
	± 1	titre 8	6,3 %
	± 4	titre 16	25 %
	± 9	titre 32	56 %
Total per sample: n = 16		Success (only evaluated results): evaluation	

Set 3**(760) Crossmatch**

S1	All results	>>> 115	Crossmatch successful	100 %
Total per sample: n = 115		Success: 100 %		
S2	All results	1	Crossmatch not successful	0,87 %
		>>> 114	Crossmatch successful	99 %
Total per sample: n = 115		Success: 99 %		
Total success: 99 %				

(761) Crossmatch (segment K1)

S1	(0) not specified	>>> 115	Positive test	100 %
Total per sample: n = 115		Success: 100 %		
S2	(0) not specified	> 39	Negative test	34 %
		>>> 76	Positive test	66 %
Total per sample: n = 115		Success: 100 %		
Total success: 100 %				

(762) Serve transfusion product (segment K1)

S1	(0) not specified	± 112	Impossible, risk of haemolysis	98 %
		± 1	Decision depends on results of other tests not performed in our laboratory	0,88 %
		± 1	Only if more suitable products are not available	0,88 %
Total per sample: n = 114		Success (only evaluated results): evaluation		
S2	(0) not specified	± 79	Impossible, risk of haemolysis	69 %
		± 27	Decision depends on results of other tests not performed in our laboratory	24 %
		± 4	Only if more suitable products are not available	3,5 %
		± 4	Possible	3,5 %
Total per sample: n = 114		Success (only evaluated results): evaluation		

(764) Crossmatch (segment K2)

S1	(0) not specified	>>> 102	Negative test	89 %
		>>> 13	Positive test	11 %
Total per sample: n = 115		Success: 100 %		
S2	(0) not specified	1	Negative test	0,87 %
		>>> 114	Positive test	99 %
Total per sample: n = 115		Success: 99 %		
Total success: 99 %				

(765) Serve transfusion product (segment K2)

S1	(0) not specified	± 22	Impossible, risk of haemolysis	19 %
		± 62	Decision depends on results of other tests not performed in our laboratory	54 %
		± 17	Only if more suitable products are not available	15 %
		± 13	Possible	11 %
Total per sample: n = 114		Success (only evaluated results): evaluation		
S2	(0) not specified	± 111	Impossible, risk of haemolysis	97 %
		± 2	Decision depends on results of other tests not performed in our laboratory	1,8 %
		± 1	Only if more suitable products are not available	0,88 %
Total per sample: n = 114		Success (only evaluated results): evaluation		

st_kl

End of report

Printed: 11.06.2021